Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection After Kidney Transplantation- A Single-Arm, Two-Dosing-Regimen, Phase I/II Study.
Wei Y, Chen X, Zhang H, Su Q, Peng Y, Fu Q, Li J, Gao Y, Li X, Yang S, Ye Q, Huang H, Deng R, Li G, Xu B, Wu C, Wang J, Zhang X, Su X, Liu L, Xiang AP, Wang C.
Wei Y, et al. Among authors: su q, su x.
Front Immunol. 2021 Jun 25;12:662441. doi: 10.3389/fimmu.2021.662441. eCollection 2021.
Front Immunol. 2021.
PMID: 34248942
Free PMC article.
Clinical Trial.